DKK1 and sclerostin are early markers of relapse in multiple myeloma.

Recent studies have shown that Dickkopf-related protein (DKK1) and sclerostin decrease when a complete response (CR) is obtained after chemotherapy in myeloma multiple (MM). To study variations in DKK1, sclerostin and P1NP in patients treated for MM, between complete response (CR) and relapse, we carried out a prospective study ancillary to the IFM 2009 protocol (IFM). The aim of IFM was to compare progression-free survival between patients treated with chemotherapy with or without transplantation. We selected 69 patients who reached CR and relapsed. We assayed by ELISA: DKK1, sclerostin and P1NP at 3 end points T1: CR, T2: 4 months before relapse and T3: relapse. There was a significant increase in DKK1 and sclerostin between T1, T2 and T3. (DKK1 medians (IQR): T1 = 30 pmol/l (20.4–41.1), T2 = 37.4 pmol/l (29.8–49.4), p  < 0.0001, T3 = 42 pmol/l (33.8–55.5), p < 0.0001 sclerostin medians (IQR): T1 = 0.57 (0.47–0.69), T2 = 0.62 ng/ml (0.53–0.79), p < 0.0001, T3 = n0.64 ng/ml (0.56–0.79), p  = 0.005). No significant variation was detected in the levels of P1NP. No association was observed between the characteristics of the MM, or the treatment received and the variation between T1–T3 for DKK1, sclerostin or P1NP. A significant increase in DKK1 and sclerostin was observed four months before relapse. [ABSTRACT FROM AUTHOR]